Reporting: VP Global Commercial Head Oncology. Team: 6 Country Directors and the 4 Swiss team members (70 team members in 7 EU subsidiaries & Switzerland). Responsible for oncology commercial operations across European affiliates (Lung Cancer / SCLC, Sarcoma, OvarianCancer). Leadership and management of local Marketing, Sales, and Medical Affairs teams. Yondelis® (Trabectedin) life-cycle management and Zepzelca® (Lurbinectedin) European launch plans. Full operational and commercial responsibility for PharmaMar Switzerland: strategy, P&L supervision, launch excellence, regulatory alignment, and business performance. Cross-functional coordination with Global/Regional Medical Affairs for evidence generation, scientific narrative development, and new indication readiness. Successful Yondelis® life-cycle management, retaining 75% market share 3 years after loss of patent. Double-digit growth for Yondelis® Switzerland in both value and units. Best global launch of Zepzelca® in Switzerland, reaching 65% share and establishing it as the standard of care in 2L SCLC. Led EU pre-launch activities for 1L ES-SCLC (Atezolizumab/Lurbinectedin), including forecasting, competitive scenario planning, KOL mapping, scientific platform alignment, and pre-approval access strategy. Directed Switzerland launch preparation and early execution for 1L ES- SCLC: pricing & reimbursement pathway, early stakeholder shaping, formulary inclusion, integrated medical- commercial planning, and adaptation of global value narrative to local needs.

- Reporting: VP – Sales & Marketing & CEO. Team: 1 Logistic Manager, 1 Assistant, 1 KAM and 4 sales rep. Responsible for leading and managing commercial operations including retail and hospital business, sales force management, Business to Business to Consumer (B2B2C) and Business to Consumer (B2C), handling business model transition (hospital business start-up), overseeing business plan, implementation of marketing, sales, market access and regulatory affairs strategies. New business model deployment (including hospital business launch) to regain the growth path (20% growth inPortugal and 6% growth for Spain end of 2022).

Executive Committee - Reporting: Country Manager. Team: 4 District Managers, 1 Brand Manager and 40 sales reps. Gx and OTC retail marketing and sales team direction and management. Commercial strategies development and implementation according to company goals and objectives aiming to accelerate growth. Retail sales increased by 3 times, 50% customers increase, sales force expansion and increase productivity- becoming one of the best performance generic companies in Spain. First Krka OTC product launched in Spain and OTC products portfolio development.

Generic LATAM Distribution project for a British company and Genetic. Genetic Testing company expansion project (internationalization and due diligence for acquisitions).

Reporting: Commercial Director. Team: 2 District Managers, 24 Sales reps. Sales management for Gynecology - Oncology (HPV – Cervix Cancer prevention- Gardasil®) and pediatric (Rotavirus - Rotateq®, Varicella - Varivax®) private market prescriptions. Salesforce management. Sales Force Effectiveness program development, Sales plan design, development and implementation until closing date to end joint vaccines operations in Europe. Sales force effectiveness program development (Planning and coaching). Rotateq®1%YTD growth (25 M€ YTD), 50% vaccination coverage and 96% market share after 8 years in the market (most successful Merck MSD worldwideRotateq operation), Varivax® successful re-launch (16 M€ YTD and 88% market share), Gardasil® 61% Market Share.

Apr13-Jun15 Executive Committee - Reporting: Managing Director. BU Team: 1 PM, 1 assistant, 6 KAM, 3 Sales reps, 11 patient care technicians. Marketing and sales strategy design for oncology (Erbitux® cetuximab), neurodegenerative diseases (Rebif®Interferon), Fertility (Gonal® FSH, Pergoveris® FSH+LH, Ovidrel® CG, etc) and Metabolic-Endocrinology (Saizen® Growth hormone and Kuvan® orphan drug for PKU) franchises. Commercial operations, marketing and sales force development and P&L management. Business unit expansion and reorganization to achieve double-digit growth in both public market (social security) and private market (HMOs, distributors and out of the pocket). Actively coordination with regional headquarters. BU organically 50% growth and double-digit YTD growth in each franchise and ready to split in 3 different Business Units (Oncoloty, Fertility and Neurodegenerative disease / Metabolic-Endocrinology).

BU Team: 1 Product Manager, 1 Sales Manager & 13 Sales Reps. P&L management, Sales & Marketing direction of retail gynecology branded Gx products: contraception (Drospirenone) and menopause (Bisphosphonates and OTCs products), KOLs management. Business Development and WH portfolio definition and team selection & recruitment. First time co-promotion agreement with Novartis Consumer Health division. Drosiane® / Drosianelle® (Drospirenone) top 5 launches on Sandoz Spain history. 2.5M€net sales in 2012 and expected break-even on Feb 2013.

BU team: 3 Product Manager, 1 Sales Manager, 5 KAMs, 2 Tenders Specialist & 10 Sales (11 direct reports). P&L management, Market access, Sales & Marketing management of biopharmaceuticals (Biosimilar) product: Pediatric endocrinology (Omnitrope® growth hormone), Endocrinology, Oncology, hematology areas (Zarzio®Filgrastim, Binocrit® Epo alfa) and Generic product: onco-injectable & anti-infective. KOLs management and Market access management. Business Unit team selection & recruitment. From 2008 to 2010 sales increased from 0,4M€Biopharmaceuticals till 4,8M€(Top 1 Biosimilar company in themarket) & 1,8M€hospitals generics products till 2,5 M €. BU team increase from 7 to 21 employees. Best Sandoz Biopharmaceuticals country operations in term of financial ratios and business unit development.

BU team: 1 Product Manager, 1 assistant, 1 Tender Specialist and 12 KAMs. Hospital Business management (Dermatology, Neurology / Multiple Sclerosis and Pediatric Endocrinology). P&L management, Sales and Marketing direction, market access management and KOLs management. Member of Merck Serono integration team after the Merck Serono merger. BU sales increase from 14,1M€till 17,7 M € Net sales. Area Business Manager (Spain & Portugal) May03-Mar05 Reporting: BU Director Madrid